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MemoryPrevious studies suggested that estrogen plays a role in cognitive function by modulating the cholinergic trans-
mission. However, most of the studies dealing with this subject have been conducted using ovariectomized rats.
In the present studywe evaluated the effects of physiological and supra-physiological variation of estrogen levels
on scopolamine-induced amnesia in gonadally intact female rats. We used the plus-maze discriminative avoid-
ance task (PMDAT) in order to evaluate anxiety levels and motor activity concomitantly to the memory perfor-
mance. In experiment 1, female Wistar rats in each estrous cycle phase received scopolamine (1 mg/kg) or
saline i.p. 20 min before the training session in the PMDAT. In experiment 2, rats in diestrus received estradiol
valerate (1 mg/kg) or sesame oil i.m., and scopolamine (1 mg/kg) or saline i.p., 45 min and 20 min before the
training, respectively. In experiment 3, rats in diestrus received scopolamine (1 mg/kg) or saline i.p. 20 min be-
fore the training, and estradiol valerate (1 mg/kg) or sesame oil i.m. immediately after the training session. In all
experiments, a test session was performed 24 h later. The main results showed that: (1) scopolamine impaired
retrieval and induced anxiolytic and hyperlocomotor effects in all experiments; (2) this cholinergic antagonist
impaired acquisition only in animals in diestrus; (3) acute administration of estradiol valerate prevented the
learning impairment induced by scopolamine and (4) interferedwithmemory consolidation process. The results
suggest that endogenous variations in estrogen levels across the estrous cyclemodulate some aspects of memory
mediated by the cholinergic system. Indeed, speciﬁcally in diestrus, a stage with low estrogen levels, the impair-
ment produced by scopolamine on the acquisition was counteracted by exogenous administration of the hor-
mone, whereas the posttraining treatment potentiated the negative effects of scopolamine during the
consolidation phase of memory.
© 2014 Elsevier Inc. All rights reserved.1. Introduction
In the last decades, numerous studies have addressed the role of es-
trogen and its replacement in some neurodegenerative disorders,idance task; SCO, scopolamine;
; MET, metestrus; DIE, diestrus;
ersive arm; %TOA, percentage of
HI,Women'sHealth Initiative;
; RIA, radioimmunoassay; MW,
ry, Department of Physiology,
o Filho, s/n, Caixa Postal 1511-mainly Alzheimer's disease (Panidis et al., 2001; Zec and Trivedi,
2002). Estrogen has been shown to reduce cognitive impairments
through different mechanisms, such as modulation of neurotransmit-
ters, synaptic plasticity, increase of cerebral blood ﬂow, protection
against apoptosis, anti-inﬂammatory actions and antioxidant properties
(for review, see Cholerton et al., 2002). In the brain, the estrogen recep-
tors are located in several structures, including the hippocampus and
the amygdala of both humans (Osterlund et al., 2000) and rodents
(McEwen and Alves, 1999).
Estrogens are a group of steroid hormones that includes three bio-
logically signiﬁcant compounds: estrone, estradiol and estriol. Estradiol
valerate (EV), an analog of estradiol, was shown to improve some types
of memory (Hosseini et al., 2010; Vázquez-Pereyra et al., 1995). Besides
their classical genomic actions, estrogens also activate non-genomic
mechanisms through intracellular signaling pathways that are critical
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Mannella and Brinton, 2006; Sawai et al., 2002). These mechanisms
are probably involved with the short-term beneﬁcial effects of estradiol
on memory acquisition (Levin, 2005; Walf and Frye, 2008). This rapid
effect of the hormone on memory can be achieved during a two-hour
time window (Luine et al., 2003; Packard, 1998).
Many cellular and behavioral acute effects appear to require physio-
logical concentrations of estrogen higher than normal (Cornil, 2009).
Behavioral studies have also revealed that rapid changes in estrogen
bioavailability, resulting from a single injection of a high dose of estradi-
ol, modify the expression of some behaviors (sexual behavior and pain
threshold) within less than 1 h. These data indicate that the action
of estrogen in the brain can occur in different time ranges (short to
long-term), possibly combining non-genomic and genomic actions
(Balthazart et al., 2006).
In animal models, sexual hormones have shown to inﬂuence mem-
ory mainly through neuronal pathways related to the hippocampus
(McEwen, 2002). Particularly, estrogen inﬂuences learning andmemory
evaluated in hippocampus-dependent tasks (McEwen, 2002; Zec and
Trivedi, 2002). In addition, this effect is possibly associated with in-
creased acetylcholine release in the hippocampus (Dumas et al., 2006,
2008). Other investigations have suggested that a long-term depriva-
tion of estrogen decreases the functional status of the basal forebrain
cholinergic projections to the cortex and hippocampus (Gibbs, 1998).
Further, both the activity of choline acetyltransferase and the release
of acetylcholine in the neocortex, hippocampus and basal forebrain
are enhanced by estrogen (Gibbs, 2000;Marriott and Korol, 2003). Last-
ly, studies showed that estrogen increases the acetylcholine release
stimulated by potassium in the hippocampus (Gibbs et al., 1997) and
potentiates the effects of cholinergic agonists in avoidance tasks when
administered directly into the hippocampus (Farr et al., 2000). All
these ﬁndings indicate that estrogen may mediate memory processes
through modulation of the cholinergic system.
It has been suggested that a previous impairment has to be present
for the estrogen's beneﬁcial effects to occur (Gibbs and Aggarwal,
1998; Tinkler and Voytko, 2005). In this respect, scopolamine (SCO) is
a muscarinic receptor antagonist that classically induces cognitive im-
pairments in behavioral tests (Silva et al., 1999; Wallenstein and Vago,
2001). Wink and coworkers described that the loss of cholinergic stim-
uli produced by the administration of SCO is comparable to the one un-
derlying the aging processes (Wink et al., 2006). Furthermore, the
replacement with estrogen in ovariectomized rats enhances memory
acquisition and counteracts the negative effects of SCO on working
and spatial memory tasks (Fader et al., 1999; Gibbs, 1999). In this re-
spect, studies in animal models are usually conducted with ovariecto-
mized animals, and do not take into account the natural hormonal
changes in gonadally intact females (Frick, 2009).
Estrogen has also been shown to inﬂuence fear and anxiety-related
behaviors. For example, endogenous changes in estrogen levels may in-
crease women's susceptibility to anxiety disorders (Walf and Frye,
2006). In this respect, the literature shows that memory can be depen-
dent on affective contents, such as anxiety level (Silva and Frussa-Filho,
2000) and the emotional valence (negative or positive) of the events
(Labar and Cabeza, 2006). Further, the neural circuit for emotional rein-
forcement includes brain regions that are also related to memory for-
mation, i.e. amygdala, hippocampus and prefrontal cortex (Labar and
Cabeza, 2006; Mathews, 1990). Thus, the hypothesis that estrogen can
inﬂuence female rats' performance in cognitive tasks with emotional
contexts by modulating anxiety-like behavior should be considered
(Frye and Walf, 2004).
The aim of the present study was to investigate the effects of physi-
ological and supra-physiological variations of estrogen levels on SCO-
induced amnesia in gonadally intact female rats. We used the plus-
maze discriminative avoidance task (PMDAT; Silva et al., 1999; Silva
and Frussa-Filho, 2000) in order to evaluate anxiety levels and motor
activity concomitantly to the learning and memory performances.2. Methods
2.1. Animals
Three-month-old femaleWistar rats (250–300 g) were housed with
free access to food and water, in a number of 4 or 5, under controlled
conditions of temperature (23–24 °C) and a 12 h light/12 h dark cycle
(lights on 06:30 am). The rats were handled according to the Brazilian
law for the use of animals in scientiﬁc research (Law Number 11.794)
and all procedures described were approved by the local ethical com-
mittee (CEUA/UFRN no. 036/2010). Prior to the procedures all the ani-
mals were gently handled for 10 min/day for 3 days.
2.2. Drugs
Scopolamine hydrobromide (SCO, Sigma, USA) was diluted in saline
solution and given i.p. at 1 mg/kg. This dose choice was based on previ-
ous studies showing scopolamine-induced impairment in rodent mem-
ory models (Barbosa et al., 2010; Claro et al., 2006), including the task
used here (Claro et al., 1999; Silva et al., 1999). Estradiol valerate (EV,
Sigma, USA) was dissolved with absolute ethanol and sesame oil and
left overnight for evaporation. Afterward, the compound was diluted to
the correct concentration with sesame oil and given i.m. at 1 mg/kg.
Estradiol levels are considered supra-physiological at doses above
0.5 mg/ml in rodents (Cornil et al., 2006). Saline solution (SAL)
(0.9% NaCl) or vehicle sesame oil (VEH) in a volume of 1 ml/kg were ad-
ministered to controls for SCO or EV treatments, respectively.
2.3. Estrous cycle
Before the beginning of the experiments, the estrous cycle was mon-
itored by the analysis of vaginal smears under a light microscopy for
three complete cycles of 4–5 days. Vaginal secretions were collected by
the gentle introduction of plastic pipettes with distillated water in a vol-
ume of 0.1ml. Only animalswith regular cyclingwere included in the ex-
periments (approximately 95%). The four stages of estrous cycle were
determined according to the following characteristics: estrus (EST) —
predominance of corniﬁed cells; proestrus (PRO)— predominance of ep-
ithelial nucleated cells; diestrus (DIE)— predominance of leucocytes and
metestrus (MET)— similar proportion of nucleated cells, leucocytes and
corniﬁed cells (Marcondes et al., 2001; Pompili et al., 2010).
2.4. Plus-maze discriminative avoidance task (PMDAT)
The apparatus employed was a modiﬁed elevated plus-maze, made
of wood, containing two enclosed arms (50 × 15 × 40 cm), an aversive
(AV) and a non-aversive (NAV), opposite to two open arms (OA;
50 × 15 cm). The task consisted of two sessions: training and testing,
each lasting 10 min. In the training session, each rat was placed in the
center of the apparatus with body orientation toward the intersection
between the open arms. Every time the animal entered with the four
paws into the aversive enclosed arm, aversive stimuli were turned on
until the animal left the arm. The aversive stimuli were a 100-W light
and an 80 dB noise produced by a lamp and speakers placed over the
aversive enclosed arm. In the test session, the animals were again
placed in the apparatus, but without presentation of the aversive stim-
ulation (Fig. 1). All behavior experiments were performed between
1:00 and 5:00 p.m. The sessions were recorded with a digital camera
placed over the apparatus and the behavioral quantiﬁcation was per-
formed by a video-tracking software (Anymaze®, Stoelting, USA).
The percent time spent in aversive arm [%TAV= time inNAV / (time
in NAV+ AV) × 100] was used to assess aversive memory (%TAV over-
all, when the entire session was considered, and %TAV in time blocks,
when the variable was analyzed throughout the sessions). The whole
sessions durations were divided into three blocks: initial (from start to
third minute), middle (fourth to seventh minute) and ﬁnal (eighth to
Fig. 1. Schematic diagram of the behavioral task and experiments I, II and III. VEH, oil vehicle; SAL, saline; SCO, scopolamine; EV, estradiol valerate; OA, open arms; AV, aversive enclosed
arm; NAV, non-aversive enclosed arm.
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well as retrieval (ﬁrst block) and extinction in the test session.
Anxiety-like behavior was evaluated by the percent time spent in
open arms [%TOA = time in OA / (time in OA + NAV + AV) × 100]
and motor activity was evaluated by total distance traveled (m) in the
whole apparatus in both sessions. The analysis of the habituation
index [distance in training session / distance in test session (TR / TE)]
was used to evaluate the habituation to the apparatus (nonassociative
learning).
2.5. Experimental procedure
A summary of the behavioral task and experimental procedure can
be seen in Fig. 1.
2.5.1. Experiment I: Inﬂuence of estrous cycle on the scopolamine-induced
memory deﬁcit
Female rats in each phase of the estrous cycle (n= 9–13 per phase)
received 1 mg/kg SCOor SAL (0.9%NaCl) 20min before the training ses-
sion in the PMDAT. The test session was performed 24 h later, without
pharmacological treatment.
2.5.2. Experiment II: Effects of pre-training estrogen on the
scopolamine-induced memory deﬁcit
In this experiment, all animals were in DIE phase. Forty-ﬁveminutes
before the training in the PMDAT, the animals received a pre-treatment
with 1 mg/kg EV or VEH. Twenty-ﬁve minutes later, the animals re-
ceived the same treatment described in experiment I. The experimental
groups (n = 8–9) were: VEH/SAL, VEH/SCO, EV/SAL and EV/SCO. The
training was performed after 20 min, and the test session was conduct-
ed 24 h later.
2.5.3. Experiment III: Effects of posttraining estrogen on the
scopolamine-induced memory deﬁcit
In experiment III, all animals were in DIE phase. Female rats received
the same treatment as describe in experiment I. Immediately after the
training session, 1 mg/kg EV or VEH were administered. The experi-
mental groups (n = 7–8) were: SAL/VEH, SCO/VEH, SAL/EV and SCO/
EV. The test session was performed 24 h later.
2.6. Determination of estradiol levels
Female rats were euthanized to assess bioavailability of estradiol at
different time points of the experimental protocol. All animals were in
DIE phase. Control group received treatment with VEH (n= 5) and ex-
perimental groups received treatment with 1 mg/kg EV. Blood samples
were collected by decapitation in tubes containing EDTA immediately
(control group) and 45 min (n = 8), 6 h (n = 8) or 24 h (n = 9) after
the hormone injection (experimental group).The samples were placed in tubes containing EDTA and centrifuged
at 3000 rpm for 10 min. Plasma was collected and stored at −20 °C
until the assays. The concentration of plasma estradiol was determined
by double antibody radioimmunoassay (RIA) usingMP Biomedicals kits
(Orangeburg, NY, USA). The lower limits of detection were 5.0 pg/ml.
The intra-assay coefﬁcients of variation were 4.3%. All samples were
measured in duplicate and, when needed, at different dilutions. To pre-
vent inter-assay variation, all samples of the same experiment were
assayed in the same RIA. Data from estradiol concentrationwere adjust-
ed by the dilution factor and expressed in pg/ml.
2.7. Statistical analysis
All data were checked for normality using the Kolmogorov–Smirnov
test. Multivariate analyses of variance (two-way ANOVA) for the treat-
ment × cycle phase (experiment I), pre-treatment × treatment (exper-
iment II) andpost-treatment× treatment (experiment III)were applied
to %TAV, %TOA, as well as distance traveled in the apparatus in each be-
havioral session. Moreover, one-way ANOVAwas performed to analyze
estrogen levels at different time points after administration. Duncan's
post hoc was run for group comparisons.
The %TAV throughout the sessions was compared by ANOVA
with repeated measures (three-way ANOVA) for time blocks × phase ×
treatment (experiment I), time blocks × pre-treatment × treatment
(experiment II) and time blocks × post-treatment × treatment
(experiment III). In experiment I, further analysis was performed
using two-way ANOVA (time blocks × treatment for each cycle
phase). We used Bonferroni's for post hoc analysis.
Comparisons from habituation index were performed using
Kruskal–Wallis one-way analysis of variance, followed by Mann–
Whitney's U-test. All results were considered signiﬁcant at p ≤ 0.05.
3. Results
3.1. Experiment I: Inﬂuence of estrous cycle on the scopolamine-induced
memory deﬁcit
3.1.1. Learning and memory
In the training session, two-way ANOVA for %TAV during the whole
session did not reveal treatment [F(1,78)= 1.72; p= 0.19], cycle phase
[F(3,78)= 2.02; p= 0.11] or interaction [F(3,78)= 0.54; p= 0.65] ef-
fects (Fig. 2A). Three-way ANOVA for %TAV in time blocks showed a sig-
niﬁcant within-subject time effect [F(2,156) = 19.68; p b 0.001], no
interaction effects and a marginally signiﬁcant between-subject treat-
ment effect [F(1,78) = 3.39; p = 0.069]. Further, a two-way ANOVA
for %TAV in time blocks was performed to each cycle phase, revealing
signiﬁcant within-subject time effects in: MET [F(2,38) = 21.39;
p b 0.001], DIE [F(2,40) = 4.15; p = 0.023], PRO [F(2,40) = 3.53;
p = 0.038] and EST [F(2,38) = 3.41; p = 0.046]. Bonferroni's post
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Fig. 2. Effects of saline (SAL) or 1 mg/kg scopolamine (SCO) treatment across estrous cycle phases (MET: metestrus; DIE: diestrus; PRO: proestrus; EST: estrus) on learning and memory
in the plus-maze discriminative avoidance task. Mean± SE for percent time spent in aversive enclosed arm (%TAV) overall (A, B) and in time blocks (C, D) in the training and test sessions.
*p b 0.05 compared to SAL (two-way ANOVA followed by Duncan's post hoc); °p b 0.05 compared to the ﬁrst time block (repeated measures ANOVA followed by Bonferroni's post
hoc); #p b 0.05 compared to SAL (repeated measures ANOVA).
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the third blocks when compared to the initial block for both treatments
(SAL or SCO) in MET, PRO and EST phases. An interaction between time
and treatment [F(2,40) = 3.55; p = 0.038] was detected only for the
DIE phase, indicating a learning deﬁcit induced by SCO treatment in
this cycle phase (Fig. 2C).
In the test session, two-way ANOVA for %TAV during the whole
session revealed a signiﬁcant effect of treatment [F(1,78) = 20.53;
p b 0.001]. Duncan's post hoc showed a signiﬁcant increase in %TAV
for SCO compared to SAL animals in MET, PRO and EST phases, but not
in DIE (Fig. 2B). When %TAV was analyzed in time blocks, three-way
ANOVA indicated signiﬁcant within-subject time effect [F(2,156) =
3.06; p = 0.05], interaction (time block × phase × treatment)
[F(6,156) = 2.16; p = 0.049] and a between-subject treatment effect
[F(1,78)= 14.59; p b 0.001]. Bonferroni's post hoc revealed amarginal-
ly signiﬁcant increase in the third block compared to the initial block be-
tween groups. The fact that no signiﬁcant difference for treatment was
found in %TAV during the whole session in DIE is due to increasedvalues of SAL animals in this phase, which can be explained by the grad-
ual increase of %TAV across blocks in this group (Fig. 2D).
When the habituation index was analyzed, Kruskal–Wallis ANOVA
detected a signiﬁcant phase effect [H(3) = 7.96; p = 0.047]. PRO/SAL
animals showed increased habituation compared to the MET/SAL
(U = 17.5; p = 0.041; Table 1) and DIE/SAL (U = 13.5; p = 0.017;
Table 1) groups, but not to the EST/SAL group (U = 27.0; p = 0.228;
Table 1). Further, PRO/SAL habituation index was also increased com-
pared to the PRO/SCO group (U= 14.5; p = 0.003; Table 1).3.1.2. Anxiety-like behavior and locomotion
A signiﬁcant treatment effect for %TOA was revealed by two-way
ANOVA in the training session [F(1,78) = 5.31; p = 0.024], indicating
an increase of open arm exploration by SCO animals in all cycle phases.
However, Duncan's post hoc did not detect differences between groups
(Table 2). A marginally treatment effect was pointed out in the test ses-
sion by two-way ANOVA [F(1,78) = 3.76; p = 0.056].
Table 1
Effects of estrous cycle, treatment with SCO (1 mg/kg), pre- and
post-treatment with EV (1 mg/kg) in plus-maze discriminative
avoidance task. Median (minimum; maximum values) for habitua-
tion index (distance in training / distance in test sessions— TR / TE).
Experiments Habituation index
I. Estrous cycle
MET-SAL 1.0 (0.7; 1.4)
MET-SCO 1.25 (0.6; 3.3)
DIE-SAL 0.7 (0.2; 2.0)
DIE-SCO 0.9 (0.2; 2.6)
PRO-SAL 1.5 (0.8; 10.8)⁎,#
PRO-SCO 1.0 (0.4; 1.1)
EST-SAL 1.0 (0.8; 11.3)
EST-SCO 0.9 (0.4; 10.2)
II. Pre-training
VEH-SAL 1.0 (0.7; 2.0)
VEH-SCO 1.0 (0.3; 1.8)
EV-SAL 1.2 (0.4; 8.6)
EV-SCO 1.1 (0.6; 1.7)
III. Posttraining
SAL-VEH 3.3 (1.2; 4.3)
SCO-VEH 1.8 (1.0; 6.2)
SAL-EV 2.05 (1.1; 3.9)
SCO-EV 1.45 (0.5; 1.8)
⁎ p b 0.05 compared toMET/SAL (U = 17.5; p = 0.041) andDIE/
SAL (U = 13.5; p = 0.017) groups (Kruskal–Wallis ANOVA follow-
ed by Mann–Whitney's U-test).
# p b 0.05 compared to PRO/SCO group (U = 14.5; p = 0.003;
Mann–Whitney's U-test).
Table 2
Effects of estrous cycle, treatment with SCO (1 mg/kg), pre- and post-treatment with EV
(1 mg/kg) in plus-maze discriminative avoidance task. Mean ± SE for percent time
spent in open arms (%TOA) and distance traveled in both training and test sessions.
Experiments %TOA Distance (m)
I. Estrous cycle
Training session
MET-SAL 8.0 ± 2.1 16.2 ± 2.4
MET-SCO 30.3 ± 8.9 26.3 ± 2.5⁎
DIE-SAL 8.9 ± 1.8 20.6 ± 2.0
DIE-SCO 30.6 ± 10.1 24.0 ± 3.9
PRO-SAL 12.9 ± 5.4 14.7 ± 1.9
PRO-SCO 16.0 ± 6.6 18.8 ± 1.7⁎
EST-SAL 16.7 ± 4.1 16.9 ± 2.9
EST-SCO 18.5 ± 8.2 21.5 ± 2.8
Test session
MET-SAL 17.2 ± 9.2 15.1 ± 1.9
MET-SCO 6.6 ± 1.6 23.1 ± 3.2
DIE-SAL 9.6 ± 2.0 32.9 ± 6.8#
DIE-SCO 12.6 ± 2.1 26.5 ± 4.5#
PRO-SAL 9.7 ± 4.8 10.2 ± 1.9
PRO-SCO 9.4 ± 2.4 22.6 ± 1.8
EST-SAL 20.1 ± 7.2 15.4 ± 3.4
EST-SCO 5.4 ± 1.4 21.4 ± 2.6
II. Pre-training
Training session
VEH-SAL 14.8 ± 3.1 18.8 ± 1.9
VEH-SCO 59.1 ± 0.9⁎ 26.5 ± 4.9
EV-SAL 22.5 ± 6.8 18.0 ± 2.2
EV-SCO 48.2 ± 0.7⁎ 28.0 ± 3.4
Test session
VEH-SAL 19.5 ± 5.0 18.9 ± 2.8
VEH-SCO 28.4 ± 8.1 27.7 ± 1.7⁎
EV-SAL 15.7 ± 5.2 13.3 ± 3.3
EV-SCO 27.9 ± 6.3 24.8 ± 1.5⁎
III. Posttraining
Training session
SAL-VEH 5.6 ± 2.4 10.9 ± 2.4
SCO-VEH 71.3 ± 1.1⁎ 30.8 ± 5.0⁎
SAL-EV 16.6 ± 5.2 19.1 ± 2.2
SCO-EV 51.6 ± 2.1⁎ 25.5 ± 5.4⁎
Test session
SAL-VEH 2.4 ± 1.0 5.2 ± 2.0
SCO-VEH 12.4 ± 5.0 17.0 ± 3.8⁎
SAL-EV 8.1 ± 4.3 11.5 ± 3.0
SCO-EV 12.4 ± 3.8 18.3 ± 3.3⁎
⁎ p b 0.05 compared to SAL control groups (two-way ANOVA followed by Duncan's post
hoc).
# p b 0.05 compared to other phases (two-way ANOVA and Duncan's post hoc).
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niﬁcant treatment effect in the training session [F(1,78) = 7.93; p =
0.006]. Duncan's post hoc show increase in motor activity of SCO ani-
mals compared to SAL in MET and PRO phases (Table 2). A signiﬁcant
estrous cycle phase effect was detected for distance traveled in the
test session [F(3,78) = 5.58; p = 0.002]. Duncan's post hoc showed
that locomotion is higher in DIE than all other phases (Table 2).
3.2. Experiment II: Effects of pre-training estrogen effects on
scopolamine-induced memory deﬁcit
3.2.1. Learning and memory
Two-way ANOVA for %TAV during the whole training session re-
vealed a signiﬁcant effect of treatment [F(1,30) = 10.54; p = 0.003].
Duncan's post hoc showed that %TAV was increased in VEH/SCO com-
pared to VEH/SAL animals, while the EV/SCO group did not differ from
controls (Fig. 3A). The analyses for %TAV in time blocks were in accor-
dance to the analysis for the whole session (data not shown).
In the test session, two-way ANOVA detected a signiﬁcant effect of
treatment [F(1,30) = 5.56; p = 0.025] in %TAV during the whole ses-
sion, indicating that the effects of SCO on retrieval occurs regardless pre-
treatment. Duncan's post hoc did not detect differences between groups
for this parameter (Fig. 3B), which was corroborated by the analyses of
%TAV in time blocks (data not shown).
Kruskal–Wallis ANOVA did not show signiﬁcant effects [H(3) =
1.82, p = 0.60] for the habituation index (Table 1).
3.2.2. Anxiety-like behavior and locomotion
Two-way ANOVA revealed a signiﬁcant effect of treatment for
%TOA in both training [F(1,30) = 17.13; p b 0.001] and test sessions
[F(1,30) = 4.99; p = 0.033]. Additionally, in the training session,
Duncan's post hoc showed signiﬁcant increase in %TOA for VEH/SCO
and EV/SCO groups compared to VEH/SAL and EV/SAL, respectively
(Table 2).
The analysis of distance traveled by two-way ANOVA revealed sig-
niﬁcant effect of treatment in the training [F(1,30) = 7.36; p = 0.011]
and test [F(1,30) = 14.47; p = 0.001] sessions. Duncan's post hocshowed increase in motor activity of VEH/SCO and EV/SCO animals
compared to VEH/SAL and EV/SAL, respectively, in the test session
(Table 2).
3.3. Experiment III: Effects of posttraining estrogen effects on
scopolamine-induced memory deﬁcits
3.3.1. Learning and memory
In the training session, a signiﬁcant effect of treatment [F(1,26) =
12.85; p = 0.001] was detected for %TAV during the whole session by
two-way ANOVA. Duncan's post hoc showed that %TAV was increased
in SCO/VEH and SCO/EV compared to SAL/VEH and SAL/EV groups, re-
spectively (Fig. 4A), which corroborated the analyses of time blocks
(data not shown).
Two-way ANOVA showed signiﬁcant effects of treatment
[F(1,26) = 21.01; p b 0.001] and post-treatment [F(1,26) = 5.30;
p = 0.029] for %TAV during the whole test session. Duncan's post
hoc revealed that SCO/VEH presented increased %TAV compared to
SAL/VEH and SAL/EV. Also, SCO/EV showed increased %TAV compared
to all other groups, suggesting that animals post-treated with EV pre-
sented impaired performance (Fig. 4B). These effects were also found
when %TAV was analyzed in time blocks (data not shown).
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Fig. 3.Effects of the pre-treatmentwith oil vehicle (VEH) or 1 mg/kg estradiol valerate (EV) and treatmentwith saline (SAL) or 1 mg/kg scopolamine (SCO) on learning andmemory in the
plus-maze discriminative avoidance task. Mean± SE for percent time spent in aversive enclosed arm (%TAV) overall in the training (A) and test (B) sessions. *p b 0.05 compared to VEH/
SAL (two-way ANOVA followed by Duncan's post hoc).
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show signiﬁcant differences between groups [H(3) = 5.55; p = 0.135;
Table 1].
3.3.2. Anxiety-like behavior and locomotion
A signiﬁcant effect of treatment was detected for %TOA by two-way
ANOVA in the training [F(1,26) = 29.82; p b 0.001] but not in the test
session [F(1,26) = 3.29; p = 0.081], corroborating the increase of
open armexploration induced by SCO showed in the other experiments.
Duncan's post hoc showed signiﬁcant increase in %TOA for SCO/VEH and
SCO/EV compared to the SAL/VEH and SAL/EV groups, respectively
(Table 2).
Two-way ANOVA for distance traveled revealed a signiﬁcant effect
of treatment in the training [F(1,26) = 9.83; p = 0.004] and test
[F(1,26) = 8.52; p = 0.007] sessions. Duncan's post hoc showed in-
crease in motor activity of SCO/VEH and SCO/EV animals compared to
SAL/VEH in both sessions (Table 2).
3.4. Estradiol levels
One-way ANOVA detected a between-subject effect [F(3,29) =
10.05; p b 0.001] to the estradiol levels at different time ranges.
Duncan's post hoc showed an increase of the estradiol concentration
after 45 min, which remained for 24 h, with a peak after 6 h, compared
to control group in DIE phase (Fig. 5).
4. Discussion
Our results showed that the treatment with SCO impaired retrieval,
which corroborates the well-known amnesic effect of this substance.0.0
20.0
40.0
60.0
80.0
100.0
Training Session
SAL/VEH
SCO/VEH
SAL/EV
SCO/EV
*
*
A B
%
TA
V 
ov
er
al
l
Fig. 4. Effects of the treatmentwith saline (SAL) or 1 mg/kg scopolamine (SCO) andposttraining
ory in the plus-maze discriminative avoidance task.Mean± SE for percent time spent in aversiv
to SAL/VEH and SAL/EV and **compared to all other groups (two-way ANOVA followed by DuIndeed, in the test session, animals at different stages of the estrous
cycle failed to avoid the aversive enclosed arm. Treatment with SCO
also impaired acquisition, but only in animals in DIE phase. In addition,
SCO induced anxiolytic effects and increased motor activity. Finally, EV
pre-training prevented the SCO-induced acquisition impairment in
DIE phase, whereas posttraining EV potentiated the SCO-induced anter-
ograde amnesia. An overview of the results is displayed in Table 3.
In the present study, learning of the task in the different phases of
the cycle in females was investigated by the analysis of %TAV in time
blocks along the training session. Saline groups in all cycle phases
learned the task by showing a decrease of %TAV throughout the session.
SCO did not provoke deﬁcits in the task acquisition in MET, PRO and
EST animals, but this impairment was observed in DIE animals
(Fig. 2C). It should be noted that DIE is a phase with low estrogen
levels (Becker et al., 2005; Marcondes et al., 2001). In line with our re-
sults, Wallenstein and Vago (2001) showed that the acquisition
and consolidation of contextual fear conditioning was impaired by
intrahippocampal administration of SCO in female rats. However, in
that study, the estrous cycle was not analyzed. When the estrous cycle
is taken into account in different types of tasks, ﬂuctuating endogenous
levels of estrogen (Korol et al., 2004) or sex (Schmidt et al., 2009) can
inﬂuence learning by modulating the choice or shift of strategy during
acquisition of the task.
Previous studies have shown an effect of estrous cycle per se on
memory performance (Frick and Berger-Sweeney, 2001; Korol et al.,
2004; Milad et al., 2009). However, this is not unequivocal because
there are also some studies indicating lack of differences in the perfor-
mance across the cycle (Frye and Sturgis, 1995; Healy et al., 1999;
Warren and Juraska, 1997). Although in our study we did not observe
a general signiﬁcant effect of estrous cycle, differences between stages0.0
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treatmentwith oil vehicle (VEH) or 1 mg/kg estradiol valerate (EV) on learning andmem-
e enclosed arm (%TAV) overall in the training (A) and test (B) sessions. p b 0.05 *compared
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Fig. 5. Estradiol concentration at different time ranges in plasma after injection of 1 mg/kg
estradiol valerate (EV). Mean ± SE for estradiol concentration adjusted by dilution factor
(1:10). p b 0.001 *compared to control group in DIE phase and **compared to all other
groups (one-way ANOVA followed by Duncan's post hoc).
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Further, the analysis of the habituation index showedbetter habituation
of the control animals in the proestrus phase, i.e. a faster response to the
contextual recognition of the apparatus (Table 1). This result could be
related to the estrogen peak typical of this phase during the acquisition
of the task. It should be considered that the hormone levels wouldmod-
ulate aspects of learning and memory related to hippocampus-
dependent or independent tasks (habit memory, stimulus–response,
spatial and working memory, attention levels). Thus, these effects
could involve various structures (hippocampus, dorsal striatum and
amygdala) and convey the value of multiple memory systems that
could be involved in the behavioral changes observed (see Packard
and Goodman, 2012 for review).
Regarding the effects of SCO, previous studies using this paradigm
did not evaluate learning across the training session (Claro et al.,
1999; Silva et al., 1999). However, some studies with other behavioral
tasks suggested that SCO affects more speciﬁcally attention than learn-
ing andmemory (Mirza and Stolerman, 2000; Sarter et al., 2003). In ad-
dition, most researches assessed the impairment induced by this drug
especially on working and short-term memories (Buresová and Bures,
1982; Stevens, 1981). Hence, the impaired acquisition promoted by
the cholinergic antagonist could be a result of its effects on attention,
working memory, or short-term memory, all aspects of the learning
process. Conversely, at the same dose range which was used here, SCO
did not impair the acquisition in spatial and contextual tasks (Decker
et al., 1990). However, it is important to point out that all these previous
studies usedmale rats. Further, the action of SCO is probably dependent
on the type of task used, the time of injection, training experience, dose
ranges and sex.
In the test session of the ﬁrst experiment, SCO increased %TAVwhen
compared to saline-treated animals, indicating amnesic effects. In
agreement with our data, previous studies using male rodents in
this task showed that SCO also induced amnesia (Silva et al., 1999). Al-
though a general treatment effect was revealed (regardless of the stage
of estrous cycle), the difference between treatments was not shown forTable 3
Overview of the estrous cycle stages (MET: metestrus; DIE: diestrus; PRO: proestrus; EST:
estrus) and estradiol valerate (EV; 1 mg/kg) effects on scopolamine-induced amnesia, an-
xiolytic and stimulant motor actions in the plus-maze discriminative avoidance task. Ar-
rows represent increase (↑) or decrease (↓) in each behavioral parameter.
Scopolamine (1 mg/kg)
Experiments Learning Memory Anxiety Activity
I. Estrous cycle MET↑ MET↓ MET↓ MET↑
DIE↓ DIE↓ DIE↓ DIE↑
PRO↑ PRO↓ PRO↓ PRO↑
EST↑ EST↓ EST↓ EST↑
II. Pre-training EV DIE↑ DIE↓ DIE↓ DIE↑
III. Posttraining EV DIE↓ DIE↓↓ DIE↓ DIE↑rats in DIE when %TAV overall was analyzed (see Fig. 2B). This would
raise the possibility that SCOwas not effective in inducing amnesia dur-
ing this cycle stage. However, while all SCO-treated groups seem to
show the same amount of aversive arm exploration, saline-treated
rats in DIE show higher %TAV than rats in other phases. When
the %TAV was analyzed in time blocks throughout the test session
(Fig. 2D), a progressive increase in aversive arm exploration was
shown by DIE animals. This suggests that these animals retrieved the
task (low levels of exploration in theﬁrst block), but presentedmemory
extinction across the session. Conversely, SCO-treated animals in DIE
show high levels of aversive arm exploration from the beginning of
the session onward, which corroborates the presence of the amnesic ef-
fect of SCO in the other cycle phases.
In a recent study, in which estrous cycle was not considered, we ob-
served that females present lower extinction in the PMDAT when com-
pared to males (Ribeiro et al., 2010). As shown by Milad et al. (2009),
the extinction of an aversive task by female rats seems to depend on
the estrous cycle phase in which the subject is being tested. In the pres-
ent work, DIE females have shown extinction of the task, unlike the rats
in the other phases. This suggests that the lack of extinction by this gen-
der (observed in the study of Ribeiro et al., 2010) is related to the hor-
monal status.
In the second experiment, the impairing effect of SCO on acquisition
was shown again. All groups (except VEH/SCO) avoided the aversive
arm in the training session (Fig. 3A), indicating that the acute adminis-
tration of EV was able to prevent the SCO-induced impaired acquisition
in animals with lower endogenous hormone levels. Gibbs et al. (1998)
made a point of the ability for estrogen to attenuate the effect of SCO
only when the analysis was limited to animals with serum levels of es-
tradiol less than 200 pg/ml, whereas higher levels of estradiol were in-
effective. This is not what was seen in our study, in which estrogen
levels reached ten times that amount (i.e. 2000 pg/ml, see Fig. 5). Nev-
ertheless, these results are in line with the hypothesis that there is a re-
lationship between cholinergic transmission, estrogen and mnemonic
system. Some studies have addressed the importance of both endoge-
nous (Gibbs, 1996) and exogenous (Fader et al., 1999) estrogen–cholin-
ergic interaction. Most of them focused on spatial tasks, and showed
that this hormone is able to prevent SCO-induced deﬁcits, including
those on the acquisition (Gibbs, 1999). Other studies have mentioned
this interaction in areas related to emotion, such as the amygdala
(Luine et al., 1975). Previous studies from our lab demonstrated that
the performance of animals in this task can be inﬂuenced by pharmaco-
logical manipulations in the amygdala (Munguba et al., 2011; Ribeiro
et al., 2011), which corroborate a possible role of this area in the effects
described here.
The learning impairment induced by SCO occurred once again in the
training session of the third experiment (Fig. 4A). In the test session, an
effect of posttraining treatment with EV was detected, indicating that
there was an increase in %TAV (Fig. 4B), mainly in the EV/SCO group.
In contrast to what was found in experiment II, in which estrogen pre-
cluded the deleterious action of the SCO on the acquisition, posttraining
treatmentwith estrogen potentiated the retrieval deﬁcit caused by SCO.
This result is probably the outcome of hormonal inﬂuence duringmem-
ory consolidation. It has been demonstrated that estradiol inﬂuences
thememory storage in a time-dependentmanner and that thememory
enhancing effect of peripheral posttraining injection of estradiol in
ovariectomized rats is blocked by SCO (Packard, 1998).
Regarding the possible mechanisms involved in the results showed
here, Hasselmo (2006) presented the role of acetylcholine in learning
and memory on a cortical dynamics perspective. In his model, during
memory codiﬁcation (learning), high levels of acetylcholine would be
necessary in order to (1) enhance the magnitude of afferent input to
cortex through the action at nicotinic receptors and (2) concomitantly
suppress the magnitude of feedback excitation (through glutamate re-
lease) in the cortex via presynaptic inhibition by muscarinic receptors
(whichwould prevent the interference by retrieval of previous events).
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would result in a weaker inﬂuence of afferent inputs relative to the
strength of excitatory feedback, which allows a longer lasting memory.
Considering this hypothesis and the fact that estrogen is able to increase
acetylcholine release and choline acetyltransferase activity in the neo-
cortex (Gibbs, 2000;Marriott and Korol, 2003), the high levels of acetyl-
choline during learning could offset the negative action of SCO, while
this increase during consolidation would surpass the amnesic effect of
the drug.
From another standpoint, the WHI (Women's Health Initiative)
showed an increased risk of stroke and dementia inwomen onhormone
therapy and predicted that estrogen treatment would not be capable of
preventing cognitive impairment in elderly patients. Thus, it is impor-
tant to consider the possibility that administration of estrogen may
have a negative impact on the brain (Azcoitia et al., 2011; Shumaker
et al., 2003). Asmentioned above, the dose of estradiol is a critical factor
for the direction of their effects on behavior. Indeed, high doses (as used
in the present study) can impair performance on various tasks that as-
sess learning and memory (Barha et al., 2010; Galea et al., 2001;
Holmes et al., 2002). Besides a possible role of the interaction with the
cholinergic system (discussed above), recent studies bring out the role
of nitric oxide (NO) system (Sadeghian et al., 2012) and brain tissue ox-
idative damage (Khodabandehloo et al., 2013) in the involvement of the
memory deﬁcits caused by high doses of EV.
The variation of the effects of estrogen on cognitive function could be
related to the mechanism of action. Studies showed that EV is able to
up-regulate ERβ and does not affect ERα expression in the hippocam-
pus and cortex (Jin et al., 2005). In another study, ERα and the musca-
rinic acetylcholine receptors were up-regulated in the hippocampus
after ovariectomized animals compared to rats in proestrus. This effect
was abolished when estradiol was chronically replaced immediately
after the ovariectomy (Cardoso et al., 2004, 2010). In this sense, ERα
knockout mice were less vulnerable to the negative effects of a large
dose of estradiol. Thus, it is suggested that inwild type females the dam-
age triggered by high hormone levels would bemediated via this recep-
tor (Rissman, 2008).
There is evidence that high concentrations of estrogen are presum-
ably produced in the brain by local aromatase activity (see Cornil
et al., 2006 for review). Based on the fact that exogenous high doses
would mimic the natural situation in the target brain areas during be-
havioral studies, Cornil et al. (2006) proposed that supra-physiological
circulating concentrationswould be necessary to assess the rapid effects
of steroid hormones. Thus, to analyze hormone bioavailability, wemea-
sured estradiol levels at different time points after injections (Fig. 5).
The concentrations reached are equivalent to 5.61 (45 min and 24 h)
and 11.22 nM (6 h), based on the molecular weight of EV (MW =
356.5). These concentrations are required to induce effective activation
of several non-genomic signaling pathways. However, as some genomic
effects can be initiated within 30min, it is not possible to determine the
mode of action of the effects observed (Cornil et al., 2006).
Concerning anxiety-like behavior, although %TOA was increased by
the administration of SCO (Table 2), estrogen administration did not
modify this anxiolytic effect. This suggests that the modulation of cho-
linergic function by this hormone is speciﬁc to learning (Exp. II) and
memory (Exp. III) processes. It is known that changes in the endogenous
and exogenous levels of both estrogen and progesterone can alter anx-
iety behavior in rodents (Becker et al., 2005; Frye et al., 2000;
Marcondes et al., 2001; Marvan et al., 1996; Mora et al., 1996; Pompili
et al., 2010). Further, Aguiar et al. (2006) observed a decrease of anxiety
in adult female rats treated with EV. In the case of the present study, al-
though no signiﬁcant differences between the estrous cycle phases
were observed (Table 2), a gradual increase in %TOAduring training ses-
sion can be observed in the phaseswith higher hormone levels (i.e. pro-
estrus and estrus).
As far as the effects of SCO per se on anxiety are concerned, a repro-
ducible anxiolytic effect was observed across experiments. In thisrespect, while few studies have also reported that SCO has anxiolytic ac-
tivity (De-Mello and Carobrez, 2002), others have suggested anxiogenic
effects (Hughes et al., 2004; Smythe et al., 1996; Zarrindast et al., 2011).
On the other hand, it has been also reported that SCO affects visual and
auditory discrimination as well as interferes with the sensory process-
ing (Klinkenberg and Blokland, 2010). A research addressed this ques-
tion using light/dark preference in the elevated plus-maze (de Araújo
Godinho et al., 2007). The results showed that the effects on anxiety
may be confused for visual discrimination deﬁcits caused by themusca-
rinic antagonist, establishing false positives. Thus, it is still controversial
if cholinergic transmission effectively participates in the reduction of
anxiety-related behaviors. In addition, most experiments (except the
one from Hughes et al., 2004) were conducted using males and do not
bring the matter of hormonal inﬂuence on such behavior (Toufexis
et al., 2006). To our knowledge,we report for theﬁrst time that SCOpro-
motes an anxiolytic effect in female rats. In a human study comparing
genders, women presented larger antianxiety and antidepressant re-
sponse following SCO treatment than men. The authors proposed that
the interaction among cholinergic, glutamatergic transmissions and es-
trogen could be involved in the regulation of this response (Furey et al.,
2010). In our study, the anxiolytic effect of SCO appeared more promi-
nent (although not signiﬁcantly different) in themetestrus and diestrus
(see Table 2), suggesting a possible interaction of the SCO with the hor-
monal status.
Another general consequence of SCO treatment was the increase in
motor activity, evaluated by the distance traveled (Table 2). Overall,
SCO has been shown to increase motor activity in several studies
(Renfro et al., 1972; Sipos et al., 1999). Some brain areas such as the hip-
pocampus, striatum, prefrontal cortex (Day et al., 1991) and amygdala
(Nomura et al., 1994) appear to be correlated with the motor enhance-
ment produced by cholinergic blockage. In contrast, experiments using
working memory tasks have reported no effect, or even decreased
motor activity (Anisman and Kokkinidis, 1975; Feigley, 1974). Again,
the function of SCO on exploratory behavior seems to depend on exper-
imental factors (type of task, drug dose, injection time etc.).
In addition, we found an effect of estrous cycle phases on the motor
activity. Rats in DIE phase explored more the apparatus during the test
session, regardless of treatment. A possible explanation would be that
the animals did not habituate to the apparatus (displayed by a lowest
habituation index, see Table 1), lacking a natural reduction of explorato-
ry drive in a known environment.
Regarding a methodological issue, it is relevant to verify if non-
speciﬁc alterations (in anxiety levels or motor behavior, for example)
are interfering with measurements related to learning and memory
shown in the present study. In this sense, we have not found any
statistical correlations between the parameters that measure different
behaviors (data not shown), which suggests dissociation of memory
outcomes and other non-speciﬁc effects. However, the interpretation
of these effects as one-dimensional is not unequivocal. As recent
reviewed by Klinkenberg and Blokland (2010), SCO is a well-known
amnesic drug producing cognitive impairments in several behavior
tasks. However, the cognitive–behavioral effect of systemic administra-
tion of this muscarinic antagonist is not very selective and may not re-
sult from a speciﬁc effect on learning and memory processes. Thus, it
is likely that effects on learning andmemory performancewhich are ob-
served after higher doses are mediated by (1) primary effects on atten-
tion and sensory/stimulus discrimination, (2) non-speciﬁc effects on
behavior (e.g., motor activity, anxiety), and (3) peripheral side-effects
(e.g., pupil dilation, salivation). Nevertheless, in the present study, nei-
ther the anxiolytic effect nor the motor increase induced by SCO were
modiﬁed by estrogen administration, suggesting that the modulation
of cholinergic function by this hormone was speciﬁc to learning
(Exp. II) andmemory (Exp. III) processes. Further, the possibility of con-
founding effects compromising the interpretation ofmemory investiga-
tions highlights the relevance of the use of the plus-maze discriminative
avoidance task to concomitantly dissociate cognitive and non-cognitive
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Kameda et al., 2007; Melo et al., 2012; Niigaki et al., 2010).
5. Conclusion
The results suggest endogenous variations in estrogen levels across
the estrous cycle modulate aspects of cognitive function mediated by
the cholinergic system. Indeed, SCO induced acquisition impairment
speciﬁcally in DIE, a stagewith low estrogen levels, and this impairment
was counteracted by previous exogenous administration of the hor-
mone. Moreover, the posttraining treatment with estrogen potentiated
the memory impairment induced by the cholinergic antagonist. We
suggest different time courses and balance between non-genomic and
genomic actions inﬂuence the regulation and functioning of cholinergic
system during the stages of memory. Nevertheless, there is evidence of
the interaction between estradiol and other neurotransmitter systems,
and a participation of these systems in the results reported here cannot
be ruled out.
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